Ariad Pharma (ARIA) Misses Q1 Loss Views by 3c

Ariad Pharma (NASDAQ: ARIA) reported Q1 EPS of ($0.29), $0.03 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $81 thousand versus the consensus estimate of $300 thousand.

For earnings history and earnings-related data on Ariad Pharma (ARIA) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• RenovoRx regains Nasdaq minimum bid price compliance
• Deutsche Bank monitors UK auto sales as Chinese exports grow